(Q52627703)

English

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

scientific article published on 19 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

Céline Clémenson

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Erwan Jouannot

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ana Merino-Trigo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Chantal Rubin-Carrez

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

19 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

273-284

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-012-9852-4

0 references

Emerging drugs to treat squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Pharmacotherapy of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

AVE8062: a new combretastatin derivative vascular disrupting agent.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

The development of combretastatin A4 phosphate as a vascular targeting agent

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Disrupting tumour blood vessels

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

How do microtubule-targeted drugs work? An overview

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Vascular targeting agents as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Targeting the tumor vasculature: a strategy to improve radiation therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9852-4

21 January 2018

Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular occlusion and tumour cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xeno

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KHT Sarcoma Blood Perfusion Change after Single-dose X-ray Irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22810221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9852-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22810221%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52627703&oldid=1502771216"